Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevos biomarcadores y tecnologías para identificación y aislamiento de células tumorales circulantes (CTC)

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20190329001
Publicado:
01/04/2019
Caducidad:
01/04/2020
Resumen:
Un grupo de investigación español del sistema de salud pública ha desarrollado una nueva tecnología para mejorar el aislamiento, detección y caracterización de células tumorales circulantes (CTC). El proceso desarrollado permite detectar células tumorales circulantes (CTC), tanto células de fenotipo epitelial como células que presentan marcadores de transición epitelial-mesenquimal (EMT), mediante el uso de miRN-21 como biomarcador. El nuevo tipo de biomarcadores epiteliales de CTC permite pronosticar el cáncer, específicamente de colon, pulmón, mama (sin metástasis) y próstata. El grupo de investigación busca socios con el fin de establecer acuerdos de licencia (autorización para utilizar la tecnología) y cooperación técnica (colaboración con otros grupos de investigación, empresas y fundaciones para adaptar las tecnologías a aplicaciones biológicas y terapéuticas).

Details

Tittle:
New biomarkers and technologies for circulating tumor cells (CTC) identification and isolation
Summary:
A Spanish research group of the public health system has developed a new technology for improving circulating tumor cells (CTCs) isolation, detection and characterization. A license agreement or an agreement for a public or private partnership for the further development of the patented technology is sought.
Description:
Metastasis is responsible for the vast majority of cancer-related deaths. During this process, circulating tumour cells (CTCs) are generated, spread from the primary tumour, colonize distant organs and lead to overt metastatic disease. During the past decade a growing interest in CTCs has spread out across the oncology field, especially looking at their capacity as prognostic elements of cancer.

Despite important progresses in understanding and detecting CTCs, most of the assays still have low sensitivity; mainly due to the use of a few epithelial biomarkers to identify and isolate them from whole blood.

A Spanish hospital research group has designed a procedure to detect circulating tumor cells (CTCs), both circulating tumor cells of phenotype epithelial as circulating tumor cells that present Epithelial-Mesenchymal Transition (EMT) markers using miRNA-21 as a biomarker.

The research group is looking for the following collaboration:
-License agreement: framework of authorizing the interested parts to use the technology.
-Technical cooperation agreement: to collaborate with other research teams, companies or foundations to adapt the technologies to biological and therapeutic applications.
Advantages and Innovations:
- The heterogeneity present in the CTCs implies the existence of different subpopulations that cannot be isolated and detected with the mere use of epithelial markers.
- The new procedure developed will allow the incorporation of mesenchymal markers to the isolation and detection devices of CTCs that will allow the identification of these subpopulations of CTCs with characteristics of mesenchymal cells.
- The identification of these subpopulations will also allow the selection of therapies directed against tumor cells of epithelial origin that present these mesenchymal or semi mesenchymal phenotypes, in a more individualized and more specific way.
- New group of CTC´s epithelial biomarkers for prognosticating cancer. More specifically: colon cancer, lung cancer, breast cancer (non-metastatic breast cancer) and prostate cancer.
Stage of Development:
Available for demonstration
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
PCT patent application

Partner sought

Type and Role of Partner Sought:
The research team wants to collaborate with researchers, companies and foundations that are interested in adapting chemical tools to biological and therapeutic applications.

The research team is looking for license agreements or an agreement for public or private partnership for the development of technology.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001005 Diagnósticos, diagnosis
06001012 Investigaciones médicas